When my oncologist will consider Chemotherapy treatment for me?

If you diagnosed with cancer Chemotherapy treatment might be considered. Chemotherapy is a medicated therapy which aims to shrink and erase cancerous cells and allow control over the disease.

and what are the side effects?

Unlike surgery or radiation, chemotherapy works all over the body and is not focused. This means that it can eliminate cancerous lesions, such as metastasis, that have developed in various organs of the body. Chemotherapy usually has serious side effects with varying degrees of difficulty and you may experience hair loss, loss of appetite, changes in exits, fatigue, infections, bleeding, pain, mood changes, muscle pain, loss of fertility and more. Please share it with your HCPs

How do I get the chemotherapy?

There are different types of chemotherapy The common is intravenous infusion There are chemotherapy drugs that are given orally by a pill.

When my oncologist will consider breast cancer surgery for me?

If you diagnosed with non-metastatic breast cancer surgery is a first and preferred option according to all standard protocols. The surgery’s goal is to remove the tumor in its entirety without harming the breast or its function. At present, multiple innovative surgeries are offered to patients, which allow reduction of the health and cosmetic damages caused to the breast. It is considered a success when a tumor is removed in full, however, not all surgeries are necessarily so. At times the tumor is branched and can only be partially removed. In patients with genetic disposition there are cases where both breasts are removed in order to prevent a recurrence of the disease, for example patients who are BRCA gene carriers.

What kinds of breast cancer surgery can be right for me?

There are several types of surgeries that your oncologist may consider for you, and this of course depends on the size of the tumor, the Stage and its location, for example:

• Partial removal - Breast-conserving Surgery (Lumpectomy)
• Complete removal - Mastectomy, sometimes radical mesectomy will be done
• Prophylactic Mastectomy
• Breast-conserving Surgery (Lumpectomy)

Two main types of treatment may be offered to patients before and after breast cancer surgery

• Treatment prior to surgery is known as ‘Neoadjuvant'
• Post-surgery treatment, also known as ‘Adjuvant’

Good Luck! To read more about breast cancer >>

Torisel®, temsirolimus,

1. Renal cell carcinoma - Torisel is indicated for the first-line treatment of patients with advanced renal cell carcinoma (RCC)
2. Mantle cell lymphoma - Torisel is indicated for the treatment of adult patients with relapsed and/or refractory mantle cell lymphoma (MCL)

Sutent®, Sunitinib, is anti cancer drug indicated for:

• For treatment of gastrointestinal stromal tumor, GIST.
• For treatment of advanced renal cell carcinoma, aRCC.
• For treatment of differentiated pancreatic neuroendocrine tumors, pNET, that have progressed or cannot be removed with surgery.

Votrient®, Pazopanib, is a type of medicine called a protein kinase inhibitor. It works by inhibiting the activity of proteins that are involved in the growth and spread of cancer cells. Votrient is used in adults to treat:

• kidney cancer that is advanced or has spread to other organs
• certain forms of soft tissue advanced sarcoma - a type of cancer that affects the supportive tissues of the body. It can occur in muscles, blood vessels, fat tissue or in other tissues that support, surround and protect the organs.

Xtandi®, Enzalutamide, is indicated for:

• the treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (CRPC)
• the treatment of adult men with metastatic CRPC who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated
• the treatment of adult men with metastatic CRPC whose disease has progressed on or after docetaxel therapy

Eulexin®, Flutamide is indicated for use in combination with LHRH agonistic analogues for the treatment of metastatic prostatic carcinoma (stage d2). To achieve the benefit of the adjuctive therapy with eulexin, treatment must be started simultaneously using both drugs.

Frimagon®, Degarelix, is anti cancer drug indicated for the treatment of adult male patients with advanced hormone dependent prostate cancer.

Decapeptyl, Triptorelin,  is indicated for precocius puberty, prostatic cancer, endomethriosis, uterus myomatoses and IVF

Ibrance®, palbociclib, is a kinase inhibitor indicated for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with • an aromatase inhibitor as initial endocrine based therapy in postmenopausal women e.g. Letrozole or • fulvestrant in women with disease progression following endocrine therapy To Read More>>

Bicalutamide is anti cancer drug for the treatment of advanced prostate cancer in combination with LHRH analog therapy or surgical castration.

Casodex is the brand name of Bicalutamide - for prostate cancer

Erleada®, Apalutamide, is an androgen receptor inhibitor indicated for the treatment of patients with non-metastatic castration resistant prostate cancer, NM-CRPC.

Abiraterone acetate is a prescription drug, hormone therapy, that inhibits CYP17 enzyme, and is given together with prednisone for the treatment of men with metastatic castration resistant prostate cancer who have already received prior chemotherapy containing docetaxel.  

Zytiga® is the commercial name of the hormonal drug Abiraterone Acetate

Jeventa® is the brand name of the chemotherapy medication - Cabazitaxel Jeventa® is indicated in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer previously treated with a docetaxel- containing treatment regimen.

Low level of neutrophil See Neutrophil

A type of white blood cell that helps the body fight infections

Folfirinox is a combination of 4 anti Pancreatic Cancer drugs:

1. Leucovorin - Folinic acid
2. Adrucil®, (Fluorouracil, 5-FU) - chemotherapy
3. Camptosar®, Campto®, (Irinotecan) - chemotherapy
4. Eloxatin®, (Oxaliplatin) - chemotherapy

Targeted Therapy works by targeting specific genes or proteins to help stop cancer growth and spread. Herceptin, Herceptin®, for breast cancer is an anti-HER2 antibody that belongs to this family of treatments.

n imaging procedure in which a computer is connected to an X-ray machine and creates a series of detailed pictures of different areas of the body. Each tissue in the body absorbs radiation and returns radiation differently. The pictures are taken from different angles and are then processed to create a three-dimensional picture. Sometimes a contrast substance is injected into a vein or can be swallowed. The contrast material causes the tissues and organs to appear more clearly. CT can be used to help diagnose diseases, plan treatment, or find out how treatment works. The test is also called CT scan, CAT scan.

A rare and particularly violent type of squamous cell epithelium cancer which usually appears in the midline of the body and most often characterized by a mutation called NUTM1. United States reports 20-30 cases a year.

Protein in a cell that participates in cell division processes and is also an oncogen. BRAF mutations appear in different cancers. The drugs and Moraphenib (generic name: Vemurafenib, trade name: Zelboraf^®) and Debrafenib (generic name: Tafinlar^®) are given to patients with mutations in BRAF.

Multikinase inhibitor are group of drugs which has demonstrated both anti proliferative and antiangiogenic properties. For example: Sorafenib  

Nexavar®, Sorafenib is anti cancer drug multikinase inhibitor,  film coated tablets, indicated for the treatment of:

• Renal cell carcinoma Nexavar is indicated for the treatment of patients with advanced renal cell carcinoma.
• Hepatocellular Carcinoma Nexavar is indicated for the treatment of patients with hepatocellular carcinoma see section
• Differentiated thyroid carcinoma Nexavar is indicated for the treatment of patients with progressive, locally advanced or metastatic, differentiated (papillary/follicular/Hürthle cell) thyroid carcinoma, refractory to radioactive iodine.

To Read More>>

CNS HGNET-BCOR, Central Nervous System Gigh Grade Neuroepithelial Tumor with BCOR alteration, is a rare cancerous tumor develop in the central nervous system, CNS, among young children.

BCOR is a gene that encodes BCL-6 corepressor protein.

Neuroblastoma is is a type of cancer which originates in nervous system. It is most commonly starts in adrenal gland, but it can also develop in the neck, chest, stomach, or pelvis. The disease is common among infants and children.

DIPG, diffuse Intrinsic Pontine Glioma, is a type of cancer which originates in the brain and made of brain cells known as “gliomas.” DIPG is a pediatric disease. The average age of diagnosis is 4 to 11, and the disease accounts for about 10-15% of all brain tumors among children. Some adults have the disease as well.

What is metastatic melanoma?

Metastatic melanoma, Stage 4 or stage IV melanoma is a cancer that started in a spot, sore or mole and its cells have spread to other body organs, distant from the origin, where they created new lesions. These lesions are called “metastases” and are made of melanoma cancer cells. Melanoma cancer metastases may appear in the bones, liver, lungs and brain. The formation of metastases is life-threatening. Even though the cancer has spread to other organs, it is still defined as a melanoma cancer and is treated as such. In this manner for example, a lesion in the lung that is a metastasis of melanoma cancer shall be treated with melanoma drugs and not lung cancer drugs.

What are the causes of metastatic melanoma?

The main cause of skin cancer is exposure to the sun’s rays, particularly ultra-violet (UV) rays. Light toned skin, a tendency to moles and freckles, a family history of skin cancer, and older age, constitute risk factors for skin cancer. The primary recommendation for people belonging to these categories is to avoid direct exposure to the sun and be sure to use sun protection, such as sunscreen lotions, sunglasses, and clothes with full body cover.

What are the advanced treatments for melanoma?

The existing therapies used on stage 4 metastatic melanoma are not curative and this is a source to the need for innovative and effective treatment strategies in order to fight the disease. The National Cancer Institute, NCI, highlights the fact that for stage 4 melanoma patients, the best treatment option is to join one of the many clinical trials existing worldwide aiming to increase their chances of therapeutic success. Currently, every patient will be offered the standard protocols. Sometimes the oncologist may suggest integrating these therapies with trials carried out in the institute. Advances in cancer therapies may be found in clinical trials prescribing cutting edge, innovative drugs, some of which have...

Ketruda® is a cancer drug which belongs to the group of immunotherpy drugs. This drug is FDA approved for different cancer indications and may also be available through: Clinical trials. There are numerous clinical trials with Ketruda® around the globe where cancer patients may be enrolled and receive it for free as long as they participate in the trial Private health insurance coverage for cancer drugs. The cost of Ketruda® is 

• 50 ml vial - around 2,600$ US
• 100 ml - around 4,300$ US

E&OE

Breast cancer incidence is strongly related to age, with the highest incidence rates being in older people. In the UK in 2013-2015, on average each year a quarter (25%) of new cases were in people aged 75 and over. Age-specific incidence rates rise steadily from around age 30-34 and more steeply from around age 70-74. The highest rates are in the 90+ age group for males and the 85 to 89 age group for females. Incidence rates are significantly lower in males than females in a number of (mainly older) age groups. The gap is widest at age 45 to 49, when the age-specific incidence rate is 423 times lower in males than females. To Read More>>

Breast cancer in men occurs in about 1% of the total breast cancer cases. It is mostly appears after the age of 50 and for genetic tendency among men with BRCA1, BRCA2 gene mutations. It can also appear in men who have breast tissue, who were exposed to estrogen, have hormonal imbalance and more. Disease management includes diagnosis, follow-up and treatment similar to breast cancer in women.

Keytruda® is a medicine that may treat certain cancers by working with the immune system, also called immunotherapy. Keytruda can cause the immune system to attack normal organs and tissues in any area of the body and can affect the way they work. These problems can sometimes become serious or life-threatening and can lead to death. Common side effects of Keytruda include: feeling tired, pain in muscles, bones or joints, decreased appetite, itching, diarrhea, nausea, rash, fever, cough, shortness of breath, and constipation. In children, feeling tired, vomiting and stomach-area (abdominal) pain, and increased levels of liver enzymes and decreased levels of salt (sodium) in the blood are more common than in adults. Call or see your doctor right away if you develop any symptoms of the following problems or these symptoms get worse:

• Lung problems (pneumonitis). Symptoms of pneumonitis may include: shortness of breath, chest pain, new or worse cough.
• Intestinal problems (colitis) that can lead to tears or holes in the intestine. Signs and symptoms of colitis may include: diarrhea or more bowel movements than usual, stools that are black, tarry, sticky, or have blood or mucus, severe stomach-area (abdomen) pain or tenderness.
• Liver problems (hepatitis). Signs and symptoms of hepatitis may include: yellowing of the skin or the whites of the eyes, nausea or vomiting, pain on the right side of the stomach area (abdomen), dark urine, feeling less hungry than usual, bleeding or bruising more easily than normal.
• Hormone gland problems (especially the thyroid, pituitary, adrenal glands, and pancreas). Signs and symptoms that the hormone glands are not working properly may include: rapid heart beat, weight loss or weight gain, increased sweating, feeling more hungry or thirsty, urinating more often than usual, hair loss, feeling cold, constipation, the voice gets deeper, muscle aches, dizziness or fainting, headaches that will not go away or unusual...

Keytruda®, Pembrolizumab, is an innovative, anti cancer monoclonal antibody  immunotherapy drug. The drug blocks the link between the cancer cell PD-L1 ligand, to a patient's immune system PD-1 receptor , helping the immune system kill the cancer cells. To read more:

• What is Keytruda® is and what it is used for>>
• Keytruda side effects>>

 

Acral melanoma is Melanoma that appears in the hands, feet, or under the nails  

Pancreatic cancer is usually discovered in later stages, as this is an internal organ. Early detection of cancer greatly increases the chances for successful treatment and on therapeutic success. Therefore, it is recommended to consult with a specialist regarding the appearance of any of the following symptoms:

• Jaundice (yellowing of the skin and the white of the eyes)
• Pain in the upper or middle abdomen and in the back
• An unexplained loss of weight
• Loss of appetite
• Diabetes
• Fatigue
• Depression

If the cancer is metastatic, meaning has sent metastases to distant organs such as the liver, lungs, bones, it might cause the following:

• Bone pain (such as back pain or pain in the thighs)
• Changes in the nervous system, such as: headaches, weakness or numbness of the arm or leg, dizziness, balancing issues or attacks
• Appearance of lumps close to the body’s surface

What is Keytruda (Keytruda®)?

Keytruda, pembrolizumab, is a prescription medicine, an innovative breakthrough drug, humanized monoclonal antibody. Keytruda belongs to the “immunotherapy” drugs that help the immune system attack the tumor. This contrasts, for example, with chemotherapy that directly affects tumor cells. Keytruda and immunotherapy is therapeutic strategy has revolutionized the treatment of cancer in recent years and is one of the most studied strategies in the world for many types of cancer and different stages of treatments.

What is Keytruda used for?

Keytruda is prescribed by an oncologist and is used to treat various types of cancer, for example: Advanced melanoma skin cancer when the disease has spread or cannot be removed by surgery. Advanced non small cell lung cancer, NSCLC, for patients with positive for PDL1 and not received chemotherapy and the tumor express EGFR or ALK gene/mutation. Other cases can be for patients who received platinum chemotherapy and it is no longer working and the patients tumor express EGFR or ALK gene/mutation. Other cases can be patients that also received an EGFR or ALK inhibitor medicine and it did not work any more. Advanced head and neck squamous cells cancer, HNSCC. if the disease has returned or spread and previous platinum chemotherapy  is no longer working. Hodgkin lymphoma, cHL, in adults and children if the disease has returned and if the patients received 3 or more types of treatment. Bladder and urinary tract cancer, urothelial carcinoma – for  metastatic disease or patients who can not receive cisplatin, or cases of a disease that progresses during chemotherapy treatment. Cancer types among adults and children that is shown by a laboratory test to be a microsatellite instability high (MSI-H), or a mismatch repair deficient (dMMR) solid tumor. Here there are a few points to consider, for example the cancer has spread or cannot be removed by surgery and there are no...

Changes in the breast, nipple or armpits in women and men may be a warning sign for the development of breast cancer but not necessarily.

Early detection has a decisive influence on how the disease is treated and on treatment outcomes.

Therefore, it is recommended that you consult a specialist physician for the appearance of any of the following symptoms:

• Lump or swallowing of the breast - Can be manually felt or seen in an ultrasound or mammogram examination.
• Nipple inversion - Reverses the side of the nipple and pulls it into the breast, enlarged nipple, bleeding, swelling, inflammatory or pulled inside.
• Lumps in the armpit - Can be manually felt or seen in an ultrasound or mammogram examination.
• Redness, inflammation, or rash (Redness / Rash) - Redness or rash that are sometimes accompanied by itching, on the breast, on the nipple, on one or two of the breasts.
• Bloody Discharge from the nipple - A bloody nipple discharge on one side or both nipples.
• Yellow Discharge from the nipple - White, yellow, translucent or other colors in one or both nipples.
• Sink in the breast or texture of "orange peel" (Dimpling) - Skin roughness or thickening of tissue in the breast or near the armpit, sometimes accompanied by a feeling of local redness and heat.
• Changes in the texture of the skin and color (Texture Change) - Changes in the appearance of the breast, or drooping of the breast a feeling of local redness and heat.

Breast Cancer Symptoms To read more

Astrocytoma is a type of stage 1 or 2  cancer tumor which originates in the brain and made of brain cells known as “gliomas.”

Anaplastic astrocytoma is a type of stage 3 cancer tumor which originates in the brain and made of brain cells known as “gliomas.”

Lucrin®, Leuprolide, is a gonadotropin releasing hormone (GnRH) agonist indicated for endometriosis, prostatic cancer, treatment of uterine fibroids for a period of up to six months. Treatment of breast cancer in pre- and peri - menopausal women in whom hormone therapy is specified.  

Zoladex®, goserelin, is anti cancer drug, belongs to a group of medicines called: LHRH analogues. Therapeutic activity Information for men:

• For treatment of prostate cancer. Zoladex works by lowering the levels of 2 testosterone, a hormone produced by the body.

Information for women:

• In women, Zoladex works by lowering the levels of estrogen, a hormone produced by the body.
• For treatment of breast cancer in premenopausal women.
• For treatment of endometriosis – a disease of the womb lining (a condition where pain is caused by excess tissue which grows within or outside of the womb).
• Helps fertility by preparing for superovulation.
• Uterine fibroids (benign growths that appear in the womb), to decrease the size of fibroids before surgery.
• Prethinning of the womb lining before surgery.

To Read More>>

Alimta®, pemetrexed, is a anti cancer drug folate analog metabolic inhibitor indicated:

• in combination with pembrolizumab and platinum chemotherapy, for the initial treatment of patients with metastatic non-squamous NSCLC, with no EGFR or ALK genomic tumor aberrations.
• in combination with cisplatin for the initial treatment of patients with locally advanced or metastatic, non-squamous, non-small cell lung cancer (NSCLC).
• as a single agent for the maintenance treatment of patients with locally advanced or metastatic, non-squamous NSCLC whose disease has not progressed after four cycles of platinum-based first-line chemotherapy.
• as a single agent for the treatment of patients with recurrent, metastatic non-squamous, NSCLC after prior chemotherapy. Limitations of Use: Alimta is not indicated for the treatment of patients with squamous cell, non-small cell lung cancer.
• initial treatment, in combination with cisplatin, of patients with malignant pleural mesothelioma whose disease is unresectable or who are otherwise not candidates for curative surgery.

Lynparza, olaparib, is anti cancer drug called a PARP inhibitor. PARP inhibitors can trigger the death of cancer cells by blocking an enzyme that helps repair DNA. Lynparza is intended for:

• for the treatment of ovarian cancer in patients carrying the BRCA mutation whom have responded to previous platinum-based chemotherapy. A test is used to determine whether the cancer you are suffering from has the BRCA mutation.
• for the treatment of metastatic breast cancer in patients with mutations in BRCA and HER2-negative, who have been treated with chemotherapy in the neoadjuvant, adjuvant or metastatic setting. If you have hormone receptor (HR)-positive disease, the recommendations are treatment with endocrine therapy.

To Read More>>  

Afinitor® , Everolimus ia an anti cancer drug which reduces the blood supply to cancer cells and can thus reduce the growth and spread of cancer cells. Afinitor can also reduce the size of kidney tumors called renal angiomyolipomas and brain tumor cells of the SEGA type, the latter two tumors are caused by a genetic disorder called Tuberous Sclerosis Complex (TSC). Indications:

• Treatment of patients with a brain tumor of the Subependymal Giant Cell Astrocytoma , SEGA, type associated with Tuberous Sclerosis Complex - TSC.
• Treatment of adult patients with a kidney tumor known as Angiomyolipoma ,AML, when the kidney tumor does not require immediate surgery. This type of tumor is connected with a genetic condition known as Tuberous Sclerosis Complex.
• Treatment of patients with advanced neuroendocrine tumors of pancreatic origin that cannot be surgically removed, that are locally advanced or have metastasized.
• Treatment of advanced hormone receptor-positive and HER2-negative breast cancer in conjunction with exemestane, in postmenopausal women without symptomatic metastatic disease spread to internal organs, after recurrence or progression of the disease, following treatment with nonsteroidal aromatase inhibitors.
• For treatment of advanced kidney cancer (Advanced Renal Cell Carcinoma ,RCC), where other treatments (so-called “VEGF-targeted therapy”) have not helped stop your disease.
• For the treatment of locally advanced, metastatic or unresectable, well-differentiated (1 or 2) non-functional neuroendocrine tumors of lung or gastrointestinal origin in adults with progressive disease.

To Read More>>

Verzenio®, abemaciclib, is indicated for treatment of breast cancer

• In combination with a non-steroidal aromatase inhibitor as initial endocrine-based therapy for the treatment of postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer
• in combination with fulvestrant for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer with disease progression following endocrine therapy
• as monotherapy for the treatment of adult patients with HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy in the metastatic setting and prior chemotherapy in the metastatic setting including taxane in adjuvant or metastatic setting. Verzenio should not be used in women after prior treatment with cyclin-dependent kinases 4 and 6 (CDK4 and CDK6) inhibitor

To Read More>>

Kisqali, Ribociclib,   is used to treat postmenopausal women with locally advanced or metastatic breast cancer, that is HR positive and HER2 negative, in combination with a non-steroidal aromatase inhibitor, as initial endocrine based-therapy. Therapeutic group: Cyclin-dependent kinase enzyme inhibitors. Kisqali contains the active ingredient ribociclib, which belongs to a group of medicines called cyclin-dependent kinase (CDK) inhibitors. Kisqali works by blocking proteins called cyclin-dependent kinases 4 and 6, which are important for the growth and division of cells. Blocking these proteins can slow down the growth of cancer cells and delay the progression of the cancer. To Read More>>

Tykerb®, lapatinib, is used to treat certain types of breast cancer (HER2-overexpressing) which have spread beyond the original tumour or to other organs (advanced or metastatic breast cancer). It may slow or stop cancer cells from growing, or may kill them. Tykerb is given in combination with other anticancer medicines. Tykerb is given in combination with capecitabine, for patients who have had treatment for advanced or metastatic breast cancer before. This previous treatment for the metastatic breast cancer must have included an anthracycline, a taxane and trastuzumab. Tykerb is given in combination with letrozole, for postmenopausal women with hormone receptor positive metastatic breast cancer that overexpress HER2 and who are candidates for hormonal therapy. To Read More>>  

Kadcyla, is approved to treat human epidermal growth factor 2 (HER2) positive breast cancer that has spread to other parts of the body (metastatic breast cancer) after prior treatment with trastuzumab (Herceptin^®) and a taxane. Prior treatment could have been for the initial treatment of breast cancer or for the treatment of cancer that had spread to other parts of the body. To Read More>>

Perjeta^®, pertuzumab, is approved for use in combination with Herceptin® (trastuzumab) and docetaxel in people who have HER2 positive breast cancer that has spread to different parts of the body (metastatic) and who have not received anti HER2 therapy or chemotherapy for metastatic breast cancer. Perjeta^® is approved for use in combination with Herceptin® (trastuzumab) and chemotherapy for:

• use prior to surgery (neoadjuvant treatment) in people with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (tumor is greater than 2 cm in diameter or node-positive). PERJETA should be used as part of a complete treatment regimen for early breast cancer.
• use after surgery (adjuvant treatment) in people with HER2-positive early breast cancer that has a high likelihood of coming back.

To Read More>>

Femara® is the commercial name  for letrozole

Femara®, letrozole, is anti cancer drug, a form of hormone therapy known as an aromatase inhibitor, which works by reducing the amount of estrogen in postmenopausal women. This medicine is a hormonal (or “endocrine”) breast cancer treatment. Growth of breast cancer is frequently stimulated by oestrogens, which are female sex hormones. Femara reduces the amount of oestrogen by blocking an enzyme (“aromatase”) involved in the production of oestrogens and may therefore block the growth of breast cancers that need oestrogen to grow. As a consequence, tumour cells slow down or stop growing and/or spreading to other parts of the body. Indications:

• Adjuvant treatment of early-stage breast cancer in postmenopausal women.
• Extended adjuvant treatment of early-stage breast cancer in postmenopausal women following standard adjuvant tamoxifen therapy.
• Treatment of advanced or metastatic breast cancer in postmenopausal women.
• Treatment of advanced breast cancer in postmenopausal women with disease progression following treatment with antioestrogens.

To Read More>>

Arimidex®, Anastrozole is a drug to treat breast cancer in post-menopausal women by aromatase enzyme inhibition To Read More>>

Exemasin is anti cancer drug indicated for the treatment of advanced breast cancer (ABC) in women with natural or induced postmenopausal status whose disease has progressed following anti estrogen therapy alone. Exemasin is also indicated for the treatment of postmenopausal women with ABC whose disease has progressed following multiple hormonal therapies. Exemasin is indicated for the adjuvant treatment of postmenopausal women with estrogen receptor positive invasive early breas cancer following 2-3 years of initial adjuvant tamoxifen therapy

Faslodex®, Fulvestrant is anti cancer drug for breast cancer. Faslodex indicated for treatment of oestrogen receptor positive, locally advanced or metastatic breast cancer in postmenopausal women not previously treated with hormonal therapy, or with disease relapse/progression on or after adjuvant endocrine therapy Faslodex, in combination with the preparation palbociclib, is intended for women with advanced or metastatic estrogen receptor-positive and HER2-negative breast cancer, whose disease has progressed after  receiving prior hormonal treatment for this ailment. When used in combination with palbociclib (Ibrance), please read the palbociclib (Ibrance) patient package insert as well. Faslodex belongs to the group of medicines that block the activity of estrogen. To Read More>> Ask your Oncologist how to use Faslodex if you are not sure. The dosage and duration of Faslodex treatment will be determined by the doctor only. Read the patient leaflet guide which is enclosed to each package.

Tamoxifen is anti cancer drug that wad initially made in 1962 and indicated for:

• hormonal breast cancer
• ovarian cancer

Vinorelbine is a chemotherapy כor the treatment of non small cell lung cancer and for the treatment of advanced breast cancer

Navelbine® is the brand name of the chemotherapy medication - Vinorelbine

Navelbine® is the brand name of the chemotherapy medication - Vinorelbine

Docetaxel is a chemotherapy indicated for: Breast Cancer

• Docetaxel in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer.
• Docetaxel in combination with doxorubicin is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have not previously received cytotoxic therapy for this condition.
• Docetaxel monotherapy is indicated for the treatment of patients with metastatic breast cancer after failure of cytotoxic therapy. Previous chemotherapy should have included an anthracycline or an alkylating agent.
• Docetaxel in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumors over-express HER2 and who previously have not received chemotherapy for metastatic disease.
• Docetaxel in combination with capecitabine is indicated for the treatment of patients with metastatic breast cancer after failure of cytotoxic chemotherapy. Previous therapy should have included an anthracycline.
• Doxorubicin and cyclophosphamide followed by docetaxel in combination with trastuzumab (AC-TH) is indicated for the adjuvant treatment of patients with HER2 overexpressing, node-positive or high risk node-negative, breast cancer.
• Docetaxel in combination with trastuzumab, and carboplatin (TCH) is indicated for the adjuvant treatment of patients with HER2 over-expressing, node-positive or high risk node-negative, breast cancer.

Non small cell lung cancer

• Docetaxel is indicated for the treatment of patients with advanced non-small cell lung carcinoma.

Ovarian cancer

• Docetaxel is indicated for treatment of metastatic carcinoma of the ovary after failure of first line or subsequent chemotherapy.

Prostate cancer

• Docetaxel in combination with prednisone or prednisolone is indicated for the treatment of patients with hormone refractory metastatic prostate...